XBI State Street SPDR S&P Biotech ETF
XBI State Street SPDR S&P Biotech ETF
Unknown sector · Unknown industry
Market read
Scan convergence 4 scans as of 2026-08-17 3 bull 1 neutral converging
POC $123.87 · VWAP $123.21 · +29.5% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 related perspective
XBI Price Structure
Loading timeframes…
Peers
Every watchlist XBI belongs to, members best 30-day change first — XBI highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech
@market-etfs
@biotech-capital-cycle
@biotech-scan
@market-pulse
@etf-ideas
News (last pull)
Headlines about XBI from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 111 days ago · Apr 29 · last pull reported an error, so these may be older than they look
- Big Pharma Is Thinking Small on Deals. That’s a Boon for Biotech.
- This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.
- MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s 2026 Performance
- Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
- This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
XBI research tape
84 dated scans, research, and events, newest first — the full record.